Skyeâs CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
(NASDAQ:SKYE) SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (âSkyeâ), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for...